[ad_1]
New COVID-19 Vaccine Assays from AstraZeneca / University of Oxford revealed that a single standard dose of efficacy from day 22 to day 90 after vaccination was 76%, with no protection falling in this three-month period.
South Africa has received your first shipment of a million doses of the Covishield vaccine from India. This vaccine is based on the AstraZeneca / University of Oxford vaccine.
This vaccine is based on a chimpanzee adenovirus vaccine vector. This is a weakened, harmless adenovirus that generally causes the common cold in chimpanzees.
It was chosen as the most suitable vaccine technology for a COVID-19 vaccine, as it has been shown to generate a strong immune response from one dose in other vaccines.
It has been genetically modified so that it is impossible for it to grow in humans. This also makes it safer to give it to children, the elderly, and anyone with a pre-existing condition such as diabetes.
Chimpanzee adenoviral vectors are a well-studied type of vaccine, which has been used safely in thousands of subjects.
The AstraZeneca / Oxford University vaccine has previously been shown to be 63% to 90% effective in two doses.
An analysis of more data has now shown that the efficacy of the vaccine is greater at longer priming and boosting intervals, and that a single dose of the vaccine is 76% effective from 22 to 90 days after vaccination. .
The effect of the dosing interval on efficacy is pronounced, with the efficacy of the vaccine increasing from 54.9% with an interval of less than six weeks to 82.4% when 12 weeks or more are separated.
A single standard dose of the vaccine is 76% effective in protecting against primary symptomatic COVID-19 during the first 90 days after vaccination, once the immune system has built up this protection 22 days after vaccination, and the protection shows little evidence of decline this period.
Professor Andrew Pollard, chief investigator of the Oxford vaccine trial, said this finding supports the policy recommendation for a 12-week prime-boost interval.
Exploratory analyzes suggest that it is the dosage range and not the dosage level that has a major impact on the efficacy of the vaccine.
This is in line with previous research supporting greater efficacy with longer booster intervals performed with other vaccines such as influenza, Ebola, and malaria.
Another piece of good news is that the vaccine has the potential to reduce transmission of the coronavirus, according to swabs obtained from volunteers in the UK with a 67% reduction after the first dose of the vaccine.
The researchers expect to report data on the new variants in the coming days and expect the findings to be very similar to those already reported by other vaccine developers.
AstraZeneca / University of Oxford vaccine trial explained
Now Read: South Africa COVID-19 Vaccines Comparison In Price, Efficacy, And Delivery Date
[ad_2]
